文献速递艾滋病与性传播感染细菌感染、耐药与抗菌药物

莱索托和坦桑尼亚病毒血症儿童及青少年HIV耐药模式:GIVE MOVE试验嵌套分析

HIV drug resistance amongst children and adolescents with viraemia in Lesotho and Tanzania: a nested analysis in the GIVE MOVE trial.
PubMed 文献 · J Antimicrob Chemother · 2026-01-01

该研究对GIVE MOVE试验中莱索托和坦桑尼亚的137名病毒血症儿童及青少年进行耐药基因型检测,发现58%的参与者三药方案中三种药物均预测有活性,仅12%对核心药物耐药,提示多数病毒血症不能归因于耐药。

要点

  • 58%的病毒血症儿童及青少年三药ART方案中三种药物均预测有活性。
  • 12%的参与者对ART核心药物耐药,包括1例高水平多替拉韦耐药。
  • 耐药突变以NNRTI和NRTI相关为主,分别占146和127个。

核心结论

  • 超过半数病毒血症儿童及青少年ART方案预测完全有活性,多数病毒血症不能由耐药解释。

研究设计与样本

  • GIVE MOVE随机试验的预设分析,对两组储存样本补充进行耐药基因型检测,纳入至少一次成功耐药检测的参与者。
  • 共纳入137名6月龄至19岁以下接受ART且近期病毒血症的儿童及青少年。

主要发现

  • 58%(80/137)的参与者三药方案中三种药物预测有活性,6%(8/137)有两种,26%(36/137)有一种,9%(13/137)无药物预测有活性。
  • 共检测到312个耐药相关突变(222个主要突变,90个辅助突变),其中146个对NNRTI耐药,127个对NRTI耐药,28个对PI耐药,11个对INSTI耐药。

临床怎么用

  • 在病毒血症儿童及青少年中,耐药检测有助于识别对核心药物耐药者,但多数病毒血症需关注其他原因如依从性。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Children and adolescents with HIV have lower treatment success than adults. Suboptimal adherence and resistance to antiretroviral therapy (ART) are known aetiological factors. This preplanned analysis in the GIVE MOVE trial (NCT04233242) describes drug resistance patterns in children and adolescents in Lesotho and Tanzania. MATERIALS AND METHODS: GIVE MOVE randomized children and adolescents (6 months to below 19 years) with recent viraemia whilst taking ART to genotypic resistance testing (GRT)-informed care or usual care. Here, we conducted additional post-hoc GRT on stored samples from both groups and included participants with at least one successful resistance test. We assessed the number of drugs predicted to be active in participants' three-drug ART regimens and resistance-associated mutations. RESULTS: Amongst 137 participants, the majority were female (58%) and lived in Lesotho (77%). At their initial GRT, 69/137 (50%) were receiving protease inhibitor-based, 59/137 (43%) dolutegravir-based and 9/137 (7%) efavirenz-based ART. At that time, 80/137 (58%) participants had three, whilst 8/137 (6%) had two, 36/137 (26%) had one and 13/137 (9%) had no drugs predicted to be active in their regimens. Seventeen (12%) participants had resistance against their ART core agent, including one with high-level dolutegravir resistance.Across 312 detected resistance-associated mutations (222 major, 90 accessory), 146 conferred resistance to non-nucleoside reverse transcriptase inhibitors, 127 to nucleoside reverse transcriptase inhibitors, 28 to protease inhibitors and 11 to integrase strand transfer inhibitors. CONCLUSION: Given that more than half had an ART regimen predicted to be fully active, most viraemia in children and adolescents could not be explained by resistance.Registration: The GIVE MOVE trial was registered on Clinicaltrials.gov NCT04233242.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Schönenberger CM, Haenggi K, Ringera IK, et al. HIV drug resistance amongst children and adolescents with viraemia in Lesotho and Tanzania: a nested analysis in the GIVE MOVE trial. J Antimicrob Chemother. 2026. PMID: 41793741. doi:10.1093/jac/dkag070

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。